Pharmaceutical

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be…

1 month ago

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms

Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debtInterest…

1 month ago

Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically

TORONTO, ON / ACCESSWIRE / June 18, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

1 month ago

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in…

1 month ago

Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET

NOTE CHANGE IN DATE OF UPDATE CALL TO THURSDAY JUNE 20thCANTON, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences,…

1 month ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…

1 month ago

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

- First Patient Dosed in Expanded Access Program and Enrollment Ongoing -IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CG…

1 month ago

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in…

1 month ago

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part…

1 month ago

Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company…

1 month ago